Free tool
FAERS Monitor: Aplenzin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022108 or its brand name (Aplenzin, Bupropion Hydrobromide). Reports on generic versions are filed under their own applications.
Reports
577
Serious
380
66% of reports
Hospitalization
161
Death reported
52
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache130
- asthma117
- therapeutic product effect incomplete89
- anxiety87
- gastrooesophageal reflux disease85
- wheezing85
- dyspnoea82
- hypertension80
- depression78
- fatigue71
- drug ineffective66
- loss of personal independence in daily activities62
- burning sensation58
- fibromyalgia58
- off label use58
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 11 |
| 2010 | 22 |
| 2011 | 12 |
| 2012 | 16 |
| 2013 | 8 |
| 2014 | 10 |
| 2015 | 16 |
| 2016 | 20 |
| 2017 | 17 |
| 2018 | 20 |
| 2019 | 40 |
| 2020 | 64 |
| 2021 | 81 |
| 2022 | 79 |
| 2023 | 83 |
| 2024 | 32 |
| 2025 | 29 |
| 2026 | 17 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,582 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fibromyalgiaSignal | 58 | 87.2 | 68.3 | 4,849 |
| wheezingSignal | 85 | 52.3 | 43.0 | 4,234 |
| loss of personal independence in daily activitiesSignal | 62 | 47.1 | 37.2 | 2,755 |
| therapeutic product effect incompleteSignal | 89 | 45.7 | 37.7 | 3,852 |
| gastrooesophageal reflux diseaseSignal | 85 | 38.5 | 31.7 | 3,078 |
| asthmaSignal | 117 | 37.8 | 32.1 | 4,170 |
| burning sensationSignal | 58 | 30.2 | 23.6 | 1,611 |
| hypertensionSignal | 80 | 13.8 | 11.2 | 944 |
| depressionSignal | 78 | 12.5 | 10.2 | 822 |
| anxietySignal | 87 | 11.1 | 9.2 | 804 |
| headacheSignal | 130 | 7.6 | 6.5 | 756 |
| dyspnoeaSignal | 82 | 5.3 | 4.3 | 288 |
| fatigueSignal | 71 | 3.3 | 2.7 | 117 |
| off label useSignal | 58 | 2.4 | 1.9 | 49 |
| drug ineffective | 66 | 1.8 | 1.5 | 25 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.